Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older.
about
Infection prevention and the medical director: uncharted territoryHistory and evolution of influenza control through vaccination: from the first monovalent vaccine to universal vaccinesImmunopotentiation of trivalent influenza vaccine when given with VAX102, a recombinant influenza M2e vaccine fused to the TLR5 ligand flagellinEstimating the potential effects of a vaccine program against an emerging influenza pandemic--United StatesPhase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009.Preclinical evaluation of Vaxfectin-adjuvanted Vero cell-derived seasonal split and pandemic whole virus influenza vaccinesSeasonal influenza vaccination and technologies.Sex-based biology and the rational design of influenza vaccination strategies.Low expression of activation marker CD69 and chemokine receptors CCR5 and CXCR3 on memory T cells after 2009 H1N1 influenza A antigen stimulation in vitro following H1N1 vaccination of HIV-infected individualsMaternal vaccination for the prevention of influenza: current status and hopes for the future.Seasonal influenza vaccination of high-risk adults.Vaccination of patients with mild and severe asthma with a 2009 pandemic H1N1 influenza virus vaccine.Inactivated influenza vaccines: recent progress and implications for the elderly.Humoral and cell-mediated immune responses to monovalent 2009 influenza A/H1N1 and seasonal trivalent influenza vaccines in high-risk childrenSafety and immunogenicity of 2009 pandemic H1N1 influenza vaccination in perinatally HIV-1-infected children, adolescents, and young adults.Suggested use of vaccines in diabetes.Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysisA dose-ranging study in older adults to compare the safety and immunogenicity profiles of MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration.Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study.Comparison of Side Effects of the 2015-2016 High-Dose, Inactivated, Trivalent Influenza Vaccine and Standard Dose, Inactivated, Trivalent Influenza Vaccine in Adults ≥65 Years.Vaccines for Acinetobacter baumannii: thinking "out of the box".Optimizing benefits of influenza virus vaccination during pregnancy: potential behavioral risk factors and interventions.Different Repeat Annual Influenza Vaccinations Improve the Antibody Response to Drifted Influenza StrainsSuperior antigen-specific CD4+ T-cell response with AS03-adjuvantation of a trivalent influenza vaccine in a randomised trial of adults aged 65 and older.Human Toll-like receptor 8-selective agonistic activities in 1-alkyl-1H-benzimidazol-2-aminesInfluenza vaccination for older adults.Age and psychological influences on immune responses to trivalent inactivated influenza vaccine in the meditation or exercise for preventing acute respiratory infection (MEPARI) trialProvider knowledge of trivalent inactivated and high-dose influenza vaccinesEstimated influenza illnesses and hospitalizations averted by influenza vaccination - United States, 2012-13 influenza season.Influenza vaccine immunogenicity in patients with primary central nervous system malignancy.Influenza vaccine responses in older adults.Antibody and Th1-type cell-mediated immune responses in elderly and young adults immunized with the standard or a high dose influenza vaccine.Clinical trial to evaluate the safety and immunogenicity of a trivalent surface antigen seasonal influenza vaccine produced in mammalian cell culture and administered to young and elderly adults with and without A(H1N1) pre-vaccinationSafety of high dose trivalent inactivated influenza vaccine in pediatric patients with acute lymphoblastic leukemia.Prolonged proinflammatory cytokine production in monocytes modulated by interleukin 10 after influenza vaccination in older adultsComparison of serum hemagglutinin and neuraminidase inhibition antibodies after 2010-2011 trivalent inactivated influenza vaccination in healthcare personnel.How sex and age affect immune responses, susceptibility to infections, and response to vaccinationDoes Influenza Vaccination Modify Influenza Severity? Data on Older Adults Hospitalized With Influenza During the 2012-2013 Season in the United States.Sex-based differences in immune function and responses to vaccination.Age-associated elevation in TLR5 leads to increased inflammatory responses in the elderly.
P2860
Q26825010-DE44393D-9D6F-473F-B473-14C8710F49F4Q28079669-F7410681-FDE4-4E2A-B8DC-8FA65AE8391FQ28743939-14C7684F-108C-4ECB-8A10-31260CA60ADDQ30204154-60811B5F-6F02-4289-A88D-AC32D1845D39Q30224646-A8097033-E354-4A50-B579-33975580C2E9Q30352121-99AB0911-B612-44EB-8A78-3B7E75618448Q30360897-EA7D65D1-C467-4BAB-877D-2B534CF765EAQ30363998-0C6C08C2-2643-44A8-9279-6D6DD83496E1Q30375875-4B3196E5-6270-4769-A3DB-B6F560A1EBD9Q30386781-0067CAB4-4A78-4CC7-A1A1-71D87F7357C3Q30387979-1B411491-77EC-4404-8E43-619CC8331C3EQ30397219-D4681E6C-56FB-439C-9830-CD9DD6D4587BQ30399057-A366E304-324D-4717-A2C3-9AAC9652CDC5Q30405955-1FBA439B-D31E-4105-ACA0-7526904772B4Q30417077-9C7CEEC3-191F-4C93-ACB4-0D3E8764DD1CQ30424594-FD892E1F-260F-4132-9446-B0AB511C922DQ30891396-8EDD90BC-A85B-4BEA-BD57-A05EF0992D20Q33578064-36B5F5DB-707D-446C-88C3-E0FE60BB282EQ33588044-9DA6E7C8-D47A-4D90-BCD4-7826CE5821BBQ33629158-1B13BFF6-C089-4572-9F27-90569DCB546FQ33637895-04E5E6EB-6E76-4C66-8F24-DF2CEEF276D6Q33705792-CEA359D3-5AC9-4625-BB7D-97A89F97A294Q33899438-D153D8E6-4F5F-484E-9DB4-55198140D6ADQ34067461-D0E7DEE8-6202-48FB-B026-F1416F828CDEQ34164851-BA3D2D5F-E478-4267-B6BC-96404BC37CFEQ34247732-61CFA732-293B-4D08-A98D-B1F2850FC982Q34271597-C6347224-18B2-475B-94D0-91BD0E989A60Q34325007-0B958D9C-CB8A-4096-8927-73CA203BB3D8Q34391722-DBCA67DD-83AA-4FD5-A634-2268DC6637BEQ34511678-60E1973F-D17F-4961-8750-0439809CD74DQ34705027-60735595-3F0A-441F-A421-8B5DF3CD5637Q34761957-AC077578-A5CB-4742-A3F2-73424C26630BQ34970364-74E2C0AE-5BAE-499A-99BB-D8BE61AFA58DQ35026642-F4E149B8-42D7-4C5D-AC9E-8CF0A55ECD34Q35197357-F72EF96F-DFF5-40DF-BA35-BE75354DB77EQ35408014-C38662C1-FE03-46DF-9CB7-300172D23D66Q35527150-4BAAFE6F-E5E0-4963-95A9-E8200AD5FF97Q35589650-ADEA934E-5F0F-4FBC-9A65-EE2BE634D290Q35661949-932E0E07-00BA-4A86-98A1-DA7EF2FB8976Q35670256-51A3BA7A-993A-42BC-9D95-5ED3F5B2F6A6
P2860
Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Randomized, double-blind contr ...... lts 65 years of age and older.
@en
type
label
Randomized, double-blind contr ...... lts 65 years of age and older.
@en
prefLabel
Randomized, double-blind contr ...... lts 65 years of age and older.
@en
P2093
P356
P1476
Randomized, double-blind contr ...... lts 65 years of age and older.
@en
P2093
Ann R Falsey
Geoffrey J Gorse
John J Treanor
Jose Capellan
Nadia Tornieporth
P304
P356
10.1086/599790
P407
P577
2009-07-01T00:00:00Z